CN1505505A - 辅酶q作为活性成分的经粘膜给药的组合物 - Google Patents
辅酶q作为活性成分的经粘膜给药的组合物 Download PDFInfo
- Publication number
- CN1505505A CN1505505A CNA028092562A CN02809256A CN1505505A CN 1505505 A CN1505505 A CN 1505505A CN A028092562 A CNA028092562 A CN A028092562A CN 02809256 A CN02809256 A CN 02809256A CN 1505505 A CN1505505 A CN 1505505A
- Authority
- CN
- China
- Prior art keywords
- mucosal
- compositions
- ubiquinone
- composition
- dihydrocoenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 101
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 210000004877 mucosa Anatomy 0.000 title description 12
- 238000000034 method Methods 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 88
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 87
- 229940035936 ubiquinone Drugs 0.000 claims description 87
- 230000003647 oxidation Effects 0.000 claims description 32
- 238000007254 oxidation reaction Methods 0.000 claims description 32
- 239000000829 suppository Substances 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 239000007923 nasal drop Substances 0.000 claims description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 4
- 208000014644 Brain disease Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010048908 Seasonal allergy Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- 208000014617 hemorrhoid Diseases 0.000 claims description 4
- 208000028774 intestinal disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000032274 Encephalopathy Diseases 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000009326 ileitis Diseases 0.000 claims description 3
- 210000002200 mouth mucosa Anatomy 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000003221 ear drop Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940120293 vaginal suppository Drugs 0.000 claims description 2
- 239000006216 vaginal suppository Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 230000000699 topical effect Effects 0.000 abstract 2
- 230000009747 swallowing Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical group 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 150000003669 ubiquinones Chemical class 0.000 description 3
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- -1 spermol Chemical compound 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 125000001655 ubiquinone group Chemical group 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明涉及在保持人体健康中非常有用的辅酶Q的供给,目的在于提供一种方法和制剂,可以向难于口服给药的患者、吞咽困难的老人和患有局部紊乱引起的疾病的患者有效地提供辅酶Q。本发明发现使用经粘膜给药的包含作为活性成分的氧化辅酶Q和/或还原辅酶Q的组合物能提高血液或局部粘膜中的辅酶Q浓度,其中氧化辅酶Q和还原辅酶Q的总含量为组合物总量的0.0001-99wt%。
Description
技术领域
本发明涉及一种经粘膜给药的组合物,该组合物包含作为活性成分的辅酶Q。
背景技术
辅酶Q是分布在从细菌到哺乳动物的很多种活有机体中的必需要成分。已知辅酶Q在活有机体中经历氧化/还原循环并用作电子输送系统中的电子载体,还原辅酶Q(reduced coenzyme Q)是抗氧剂。还已知在包括人、鱼、和鸟的许多动物中,辅酶Q主要由在侧链中含有10个重复结构的辅酶Q10组成,并且在活有机体中存在的约40%-90%辅酶Q一般为它的还原形式。由于辅酶Q可以在活有机体中合成,辅酶Q并不属于维生素组,但认为辅酶Q基本与维生素一样重要。并且,人类的辅酶Q10生物合成能力随年龄增长而降低,导致活有机体中的辅酶Q10含量降低,因此需要以一些形式供应辅酶Q10。
在辅酶Q10中,氧化辅酶Q10(oxidized coenzyme Q)在临床中用作治疗充血性心力衰竭的药物。除临床应用以外,辅酶Q10用作类似于维生素的营养性补充物或营养性助剂,或用来有效地治疗变应性疾病(allergic disease)或增加运动能力。因此,已经在很多种领域中报导了氧化辅酶Q10的效果。此外,已经报导其对于脑疾病如痴呆等有效,因此可以期望氧化辅酶Q10对于治疗老年人疾病具有良好的疗效。
因此,辅酶Q10具有很高的使用价值,并且在动物的安全试验中没观察到毒性,其中采用1.2g/kg/天的高剂量辅酶Q10向大鼠连续给药52周。因此,辅酶Q10被证明为是具有高度安全性的化合物(J.Agric.Food Chem.,1999,Vol.47,P3756-3763)。然而,除了口服给药,辅酶Q10实际上仅用作皮肤药剂,因此难于向不容易口服摄入辅酶Q10的患有严重疾病的患者、老年人或幼儿给药。此外,在容易患变应性疾病的局部部位如肠道、鼻子、或耳朵,通过口服给药不能获得足够的辅酶Q浓度。因此,事实上,辅酶Q不能被有效地使用。
发明概述
本发明的目在于提供一种制剂,该制剂包含作为活性成分的辅酶Q,可以容易地用于难于进行口服给药的患者或老年人,或能有效地为很难获得足够浓度辅酶Q的局部部位提供辅酶Q。
为了解决以上问题,本发明人发现辅酶Q可以通过粘膜吸收入体内。还发现与仅包含氧化辅酶Q的组合物相比,使用包含还原辅酶Q的组合物的辅酶Q制剂获能得较高的辅酶Q血液浓度。进一步发现可以通过粘膜吸收将辅酶Q有效地输送到局部部位。
本发明的经粘膜给药的组合物包括,作为活性成分的由通式(1)表示的氧化辅酶Q和/或由通式(2)表示的还原辅酶Q:
(其中n表示1-12的整数)
(其中n表示1-12的整数),
其中氧化辅酶Q和还原辅酶Q的总含量为组合物总重量的0.0001-99wt%。该组合物可应用于人或动物。动物的实例包括宠物动物如狗、猫等,赛马,家畜如母牛、马、猪、兔、大鼠、小鼠等,鸟等。
在本发明中,“经粘膜给药的组合物”表示通过粘膜吸收入体内的剂型的组合物。在本发明中,“粘膜”包括肠、鼻粘膜、口腔粘膜、耳粘膜、阴道粘膜等。
本发明提供应用于人或动物的经粘膜给药的组合物,因此本发明也提供了一种将辅酶Q转运入身体的方法。此外,本发明提供应用于患病的人或动物粘膜的经粘膜给药的组合物,也因此提供了一种治疗疾病的方法。关于应用条件,可以根据使用的组合物剂型使用一般已知的条件。例如,在栓剂的情况下,包含辅酶Q的栓剂优选一天使用一次。在此情况下,辅酶Q的含量优选为30mg-100mg,更优选为50mg-100mg。在滴眼剂或滴鼻剂的情况下,包含辅酶Q的滴眼剂或滴鼻剂优选一天使用2次或3次。在此情况下,辅酶Q的含量优选为0.01%-10%重量比,更优选0.1%-3%重量比。
发明详述
以下详细描述本发明。
由上述通式(1)表示的化合物是氧化辅酶Q,由上述通式(2)表示的化合物是还原辅酶Q。
获得氧化辅酶Q和还原辅酶Q的方法不受限制,例如,可以使用包括如下步骤的方法:由常规已知工艺如合成、发酵、从天然来源的提取等获得辅酶Q,然后浓缩色谱洗脱物中每个级分。为获得还原辅酶Q,如需要,可以将通用还原剂如硼氢化钠、连二亚硫酸钠等加入到辅酶Q中,由常规工艺将包含在辅酶Q中的氧化辅酶Q还原成还原辅酶Q,然后用色谱浓缩获得的还原辅酶Q。也可以通过向获得的氧化辅酶Q施用还原剂而获得还原辅酶Q。
作为用于本发明的氧化辅酶Q和还原辅酶Q,如通式(1)和(2)所示,可以使用含有1-12个侧链重复单元(每个通式中的n)的辅酶。特别地,优选使用含有10个侧链重复单元的辅酶,即氧化辅酶Q10和还原辅酶Q10。
尽管本发明组合物中的辅酶Q含量适当地由应用和剂型确定,氧化辅酶Q和还原辅酶Q的总含量(当组合物仅包含氧化辅酶Q时,组合物总量的氧化辅酶Q含量;当组合物仅包含还原辅酶Q时,组合物总量的还原辅酶Q含量)下限是组合物总量的0.0001wt%,上限是99wt%。优选地,下限是0.005wt%,上限是50wt%。更优选地,下限是0.01wt%,和上限是30wt%。
当本发明的组合物包含氧化辅酶Q和还原辅酶Q两者时,还原辅酶Q占氧化辅酶Q和还原辅酶Q两者总量的重量比优选超过20wt%,更优选是40wt%或更高。含量的上限可以是100wt%或更小,优选小于100wt%,更优选98wt%或更小。
根据给药途径,本发明的经粘膜给药的组合物可以制备成如栓剂、阴道栓剂、滴鼻剂、滴耳剂、口腔粘膜敷贴剂、牙膏、锭剂、滴剂、药糖剂、口服增溶剂等剂型。上述各种剂型可以利用通常制剂使用的添加剂,通过常规的已知制剂方法来制备。
一般用于栓剂的添加剂的实例包括半合成的硬化油如Isocacao(由KaoCorporation生产)、Witepsol(由Huls Corp.生产)、Suppocire(Gattefosse Corp.)、Pharmasol(由NOF Corporation生产)、Novata(由Henkel Corp.生产)、SB碱(由Taiyo Oil K.K.生产)等;天然脂肪和油,如可可油脂、棕榈脂、棕榈种子油、棕榈油、分馏椰子油、猪油等;蜡,如羊毛脂、还原羊毛脂等;烃,如凡士林、角鲨烯、角鲨烷、液体石蜡等;高级醇,如月桂醇、鲸蜡醇、硬脂醇等;脂肪酸酯,如硬脂酸丁酯、丙二酸二月桂酯等;甘油中等链羧酸酯,如三油精、三硬脂酸甘油酯等;甘油取代的羧酸酯,如甘油乙酰乙酸酯等;聚乙二醇及其衍生物,如聚乙二醇(macrogol)、乙酰基聚乙二醇等。
一般用于滴鼻剂的制剂添加剂的实例包括生理盐水;缓冲剂,如乳酸盐缓冲剂、乙酸盐缓冲剂、磷酸盐缓冲剂等;杀菌剂和抗菌防腐剂,如对羟苯甲酸酯、丙二醇、苯索氯铵、苯扎氯铵、山梨酸或其盐、氯丁醇等;增稠剂,如聚乙烯醇、聚乙烯基吡咯烷酮、葡聚糖、海藻酸金属盐、蔗糖、明胶、甲基纤维素、透明质酸金属盐等;粉末给药用基质如结晶纤维素、α-纤维素、交联羧甲基纤维素钠、羟丙基纤维素、β-环糊精、二甲基-β-环糊精、乳糖等。
本发明的组合物可进一步包含适于各种型剂和目的的吸收促进剂。
本发明的经粘膜给药的组合物可用于医药产品。在此情况下,治疗的疾病的例子包括痔疮、自发性溃疡性结肠炎、节端性回肠炎(Crohn′s disease)、心力衰竭、脑病、脑梗塞、糖尿病、糖尿病性视网膜炎、心肌梗塞、过敏性鼻炎、花粉病、结膜炎、牙龈炎、或牙槽脓溢等。在此情况下,组合物可进一步包含除辅酶Q以外的治疗成分。
在本发明中,栓剂可包含通常用于肠疾病如痔疮、自发性溃疡性结肠炎、节端性回肠炎等的药物;或用于全身的物质,如解热镇痛药、营养性佐剂等。
在本发明中,滴鼻剂可包含通常用于过敏性鼻炎或花粉病的药物。
在本发明中,牙膏可包含通常用于牙龈炎或牙槽脓溢的药物。
本发明的经粘膜给药的组合物也可用于营养用途。在此情况下,组合物可进一步包含营养性佐剂。营养性佐剂的实例包括维生素、天然药物粗提物、草本提取物、多酚、蜂胶等。
最佳实施方式
尽管本发明参考以下实施例和制剂实施例进行进一步详细描述,本发明并不限于这些实施例。
(实施例1)
(1)试样样品1的制备
在50℃的水浴上熔融1g氧化辅酶Q10,然后加入聚乙二醇1000(PEG1000),形成10ml混合物。将获得的混合物在50℃均匀熔融混合(melt-mixed),然后在室温下固化形成直径为约5mm的圆柱形栓剂。
(2)试样样品2的制备
在50℃的水浴上熔融1g还原辅酶Q10(包含5%氧化辅酶Q10),然后加入由相同方法熔融的聚乙二醇1000(PEG1000)形成10ml混合物。将获得的混合物在50℃下均匀熔融混合,然后在室温下固化以形成栓剂。栓剂中的还原辅酶Q10含量是辅酶Q10总量的95%,在制备期间没观察到氧化。
(3)经粘膜吸收的试验
试样样品1和2各自用作试验样品。通过使用禁食1夜的雄性wistar大鼠(体重250-300g)进行试验。采用1g/kg的剂量将试验样品1或2插入每个鼠的直肠。在插入之后,随时间采集血液以测定血浆中的辅酶Q10量。血浆中的辅酶Q10量见表1。每个数值是n=10时的平均值±标准偏差。
表1
*p<0.05,**p<0.0 1,***p<0.001,Studentt检验
时间 | 血浆中的辅酶Q10量(ng/ml) | |
包含氧化辅酶Q10的栓剂 | 包含还原辅酶Q10的栓剂 | |
0 | 12.88±1.94(100) | 13.79±1.34(100) |
1 | 11.67±2.33(91) | 14.86±1.89(108) |
2 | 18.51±4.56(144*) | 17.68±3.55(128) |
4 | 15.96±3.61(124) | 21.55±4.61(156*) |
8 | 15.63±3.30(121) | 37.61±4.88(272***) |
12 | 14.75±2.99(115) | 46.11±6.09(334***) |
24 | 11.37±1.87(88) | 28.64±5.50(207***) |
如上所述,发现通过经粘膜给药的辅酶Q10栓剂,增加了血浆中的辅酶Q10量。此结果表明,由于不溶解性而仅可以口服给药的辅酶Q10,甚至当口服给药困难时,可以经粘膜给药。令人惊奇的还有与包含100%氧化辅酶Q10的辅酶Q10相比,使用包含95%还原辅酶Q10的辅酶Q10栓剂,能更大程度地增加血浆中的辅酶Q10量。因此发现包含95%还原辅酶Q10的辅酶Q10栓剂能极佳地向活有机体提供辅酶Q10。
(实施例2)粘膜透过能力的试验
由实施例1中的相同方法分别制备包含氧化和还原辅酶Q10的栓剂。通过使用每种栓剂评价辅酶Q10透过鼠结肠粘膜的能力。在试验中,以实施例1中相同的方式,将1g/kg剂量的试验样品1或2插入每只雄性Wistar大鼠的结肠。在插入之后,随时间采集每只鼠的结肠和然后充分洗涤,通过高效液相色谱(HpLC)测定结肠组织中的辅酶Q10量。结肠组织中的辅酶Q10量见表2。每个数值是n=5的平均值±标准偏差。
表2
时间 | 结肠中的辅酶Q10数量(μg/g) | |
包含氧化辅酶Q10的栓剂 | 包含还原辅酶Q10的栓剂 | |
0 | 0.88±0.21(100) | 0.73±0.15(100) |
2 | 1.22±0.31(138) | 1.78±0.56(243*) |
4 | 1.41±0.48(160) | 2.37±0.62(325**) |
8 | 1.29±0.32(147) | 2.19±0.53(300**) |
24 | 1.07±0.31(122) | 1.64±0.41(224*) |
*p<0.05,**p<0.01,Studentt检验
如上所述,发现通过辅酶Q10栓剂经粘膜给药,增加了结肠粘膜中的辅酶Q10量。此结果表明该剂型可以有效地将辅酶Q10提供到粘膜。进一步令人惊奇的是,与包含100%氧化辅酶Q10的辅酶Q10的栓剂相比,使用包含95%还原辅酶Q10的辅酶Q10的栓剂,能更大程度地增加粘膜中的辅酶Q10量。因此发现,包含95%还原辅酶Q10的辅酶Q10的栓剂能极佳地向粘膜提供辅酶Q10。
(制剂实施例1)栓剂
辅酶Q10 1.0g
聚乙二醇 总计100g
但是,辅酶Q10中,还原形式/氧化形式比为98∶2。
(制剂实施例2)滴眼剂
辅酶Q10 0.1g
甘油 1.0g
丙二醇 1.0g
Polysolvate 80 1.5g
磷酸二氢钠 0.1g
苯扎氯铵 0.005g
蒸馏水 总计100mL
使用的辅酶Q10中,还原形式/氧化形式比为98∶2。
工业实用性
本发明的组合物具有上述组成,因此能通过除口服给药之外的方法极佳地向整个身体提供辅酶Q,并在局部粘膜中积累辅酶Q。因此,该组合物对老年人或具有严重疾病的患者的医疗保健,以及对局部粘膜中出现的疾病,如变应性疾病等显示优异的效果。
Claims (18)
2.根据权利要求1的经粘膜给药的组合物,其中由通式(1)表示的氧化辅酶Q是氧化辅酶Q10,由通式(2)表示的还原辅酶Q是还原辅酶Q10。
3.根据权利要求1或2的经粘膜给药的组合物,其中该组合物用作栓剂、滴鼻剂、滴耳剂、口腔粘膜敷贴剂、锭剂、滴剂、药糖剂、口服增溶剂、阴道栓剂或牙膏。
4.根据权利要求1-3任意一项的经粘膜给药的组合物,其中该组合物用作药物。
5.根据权利要求4的经粘膜给药的组合物,进一步包括除通式(1)表示的氧化辅酶Q和通式(2)表示的还原辅酶Q之外的药用成分。
6.根据权利要求4的经粘膜给药的组合物,其中该组合物用于治疗痔疮或肠疾病。
7.根据权利要求6的经粘膜给药的组合物,进一步包括用于治疗痔疮或肠疾病的药物。
8.根据权利要求6的经粘膜给药的组合物,其中所述肠疾病是自发性溃疡性结肠炎或节端性回肠炎。
9.根据权利要求4的经粘膜给药的组合物,其中该组合物用于治疗心力衰竭、脑病、脑梗塞、糖尿病、糖尿病性视网膜炎、心肌梗塞、过敏性鼻炎、花粉病、结膜炎、牙龈炎或牙槽脓溢。
10.根据权利要求9的经粘膜给药的组合物,进一步包括用于治疗心力衰竭、脑病、脑梗塞、糖尿病、糖尿病性视网膜炎、心肌梗塞、过敏性鼻炎、花粉病、结膜炎、牙龈炎、或牙槽脓溢的药物。
11.根据权利要求1-3任意一项的经粘膜给药的组合物,其中该组合物用于营养用途。
12.根据权利要求11的经粘膜给药的组合物,进一步包括除由通式(1)表示的氧化辅酶Q和由通式(2)表示的还原辅酶Q之外的营养性辅助物。
13.根据权利要求1-12任意一项的经粘膜给药的组合物,其中将该组合物应用于人。
14.根据权利要求1-12任意一项的经粘膜给药的组合物,其中将该组合物应用于动物。
15.根据权利要求14的经粘膜给药的组合物,其中将该组合物应用于狗和/或猫。
16.根据权利要求14的经粘膜给药的组合物,其中将该组合物应用于赛马。
17.一种将辅酶Q转运入活有机体的方法,包括向人或动物粘膜应用根据权利要求1-15任意一项的经粘膜给药的组合物。
18.一种治疗疾病的方法,包括向患有疾病的人或动物粘膜施用根据权利要求4的经粘膜给药的组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP139605/01 | 2001-05-10 | ||
JP2001139605 | 2001-05-10 | ||
JP139605/2001 | 2001-05-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1505505A true CN1505505A (zh) | 2004-06-16 |
CN100438862C CN100438862C (zh) | 2008-12-03 |
Family
ID=18986353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028092562A Expired - Fee Related CN100438862C (zh) | 2001-05-10 | 2002-05-08 | 辅酶q作为活性成分的经粘膜给药的组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7754205B2 (zh) |
EP (1) | EP1388340B1 (zh) |
KR (2) | KR20060103288A (zh) |
CN (1) | CN100438862C (zh) |
AT (1) | ATE480231T1 (zh) |
AU (1) | AU2002309038B2 (zh) |
CA (1) | CA2443191A1 (zh) |
DE (1) | DE60237597D1 (zh) |
WO (1) | WO2002092067A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102503798A (zh) * | 2011-11-16 | 2012-06-20 | 中国农业科学院蜜蜂研究所 | 一种从蜂花粉中提取辅酶q10的方法及其应用 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3742602B2 (ja) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素qの安定な溶液 |
TW200304372A (en) * | 2002-03-20 | 2003-10-01 | Kanegafuchi Chemical Ind | Compositions for diabetes |
TWI322008B (en) * | 2003-01-31 | 2010-03-21 | Kaneka Corp | Fatigue improving agent including reduced coenzyme q10 |
CN1870982B (zh) * | 2003-10-31 | 2010-05-26 | 株式会社钟化 | 含还原型辅酶q的组合物 |
KR101535395B1 (ko) | 2004-01-22 | 2015-07-08 | 유니버시티 오브 마이애미 | 국소용 코-엔자임 큐10 제형 및 그의 사용 방법 |
US20090081683A1 (en) * | 2005-11-29 | 2009-03-26 | Genelink, Inc. | Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin |
JP5103374B2 (ja) * | 2006-03-13 | 2012-12-19 | 株式会社カネカ | 心機能不良改善剤または心機能維持剤 |
US20090192312A1 (en) * | 2006-04-10 | 2009-07-30 | Mitsubishi Gas Chemical Company, Inc. | Brain Function-Improving Agent, and Functional Food Containing the Improving Agent |
EP3173068B1 (en) * | 2006-05-02 | 2020-09-09 | University of Miami | Topical co-enzyme q10 formulations and treatment of wounds |
CA2721071C (en) | 2008-04-11 | 2017-10-17 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
EA201101519A1 (ru) | 2009-05-11 | 2012-10-30 | БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи | Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния |
JP6092844B2 (ja) | 2011-04-04 | 2017-03-08 | バーグ エルエルシー | 中枢神経系腫瘍の治療方法 |
WO2014088301A1 (ko) * | 2012-12-03 | 2014-06-12 | 가톨릭대학교 산학협력단 | 코엔자임 q10을 유효성분으로 포함하는 염증성 질환 또는 면역거부질환의 예방 또는 치료용 조성물 |
KR101581508B1 (ko) * | 2012-12-03 | 2015-12-31 | 가톨릭대학교 산학협력단 | 코엔자임 q10을 유효성분으로 포함하는 염증성 질환 또는 면역거부질환의 예방 또는 치료용 조성물 |
BR112015025424A2 (pt) | 2013-04-08 | 2017-07-18 | Berg Llc | tratamento de câncer usando terapias de combinação de coenzima q10 |
JP6595478B2 (ja) | 2013-09-04 | 2019-10-23 | バーグ エルエルシー | コエンザイムq10の連続注入によるがんの治療方法 |
KR20200015549A (ko) | 2017-05-17 | 2020-02-12 | 버그 엘엘씨 | 수포성 표피박리증의 치료 및 예방에서 조효소 q10 제형의 용도 |
US11471426B2 (en) | 2019-10-16 | 2022-10-18 | American River Nutrition, Llc | Compositions comprising quinone and/or quinol and methods of preparations and use thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH655005A5 (it) * | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. |
US5378461A (en) * | 1991-07-12 | 1995-01-03 | Neigut; Stanley J. | Composition for the topical treatment of skin damage |
US5660835A (en) * | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
US20020032160A1 (en) * | 1995-02-24 | 2002-03-14 | Nyce Jonathan W. | Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels |
JP3889481B2 (ja) * | 1996-08-16 | 2007-03-07 | 株式会社カネカ | 医薬組成物 |
WO1998035658A2 (de) * | 1997-02-12 | 1998-08-20 | Mse Pharmazeutika Gmbh | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon |
IL122084A (en) | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
DE19802050A1 (de) * | 1998-01-21 | 1999-07-22 | Labtec Gmbh | Zubereitung zur Freisetzung von Coenzym Q 10 in die Mundhöhle |
US6048886A (en) * | 1998-10-05 | 2000-04-11 | Neigut; Stanley | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin |
US6200550B1 (en) | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
DE19905880A1 (de) | 1999-02-11 | 2000-08-17 | Mse Pharmazeutika Gmbh | Spray enthaltend Ubichinon Qn |
DE19905879A1 (de) * | 1999-02-11 | 2000-08-17 | Mse Pharmazeutika Gmbh | Ubichinon Qn zur Behandlung von Schmerzen |
US20040034107A1 (en) | 1999-02-11 | 2004-02-19 | Mse Pharmazeutika Gmbh | Ubiquinone Qn for the treatment of pain |
US8753675B1 (en) | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
IT1316997B1 (it) * | 2000-03-02 | 2003-05-26 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di vasculopatie,che comprende propionil l-carnitina e coenzima q10. |
US6686485B2 (en) * | 2001-04-19 | 2004-02-03 | Daniel David West | Synthesis of coenzyme Q10, ubiquinone |
JP3742602B2 (ja) * | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素qの安定な溶液 |
US7708990B2 (en) * | 2004-03-23 | 2010-05-04 | Kaneka Corporation | Coenzyme Q compositions persisting in blood |
-
2002
- 2002-05-08 AU AU2002309038A patent/AU2002309038B2/en not_active Ceased
- 2002-05-08 DE DE60237597T patent/DE60237597D1/de not_active Expired - Lifetime
- 2002-05-08 CA CA002443191A patent/CA2443191A1/en not_active Abandoned
- 2002-05-08 KR KR1020067018328A patent/KR20060103288A/ko not_active Application Discontinuation
- 2002-05-08 CN CNB028092562A patent/CN100438862C/zh not_active Expired - Fee Related
- 2002-05-08 EP EP02769547A patent/EP1388340B1/en not_active Expired - Lifetime
- 2002-05-08 US US10/476,208 patent/US7754205B2/en active Active
- 2002-05-08 WO PCT/JP2002/004476 patent/WO2002092067A1/ja active IP Right Grant
- 2002-05-08 KR KR1020037013595A patent/KR100685696B1/ko not_active IP Right Cessation
- 2002-05-08 AT AT02769547T patent/ATE480231T1/de not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102503798A (zh) * | 2011-11-16 | 2012-06-20 | 中国农业科学院蜜蜂研究所 | 一种从蜂花粉中提取辅酶q10的方法及其应用 |
CN102503798B (zh) * | 2011-11-16 | 2014-07-16 | 中国农业科学院蜜蜂研究所 | 一种从蜂花粉中提取辅酶q10的方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20060103288A (ko) | 2006-09-28 |
CA2443191A1 (en) | 2002-11-21 |
US7754205B2 (en) | 2010-07-13 |
CN100438862C (zh) | 2008-12-03 |
WO2002092067A1 (fr) | 2002-11-21 |
US20040115181A1 (en) | 2004-06-17 |
KR100685696B1 (ko) | 2007-02-23 |
AU2002309038B2 (en) | 2007-05-17 |
ATE480231T1 (de) | 2010-09-15 |
EP1388340A4 (en) | 2004-12-08 |
EP1388340A1 (en) | 2004-02-11 |
DE60237597D1 (de) | 2010-10-21 |
EP1388340B1 (en) | 2010-09-08 |
KR20030092082A (ko) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1505505A (zh) | 辅酶q作为活性成分的经粘膜给药的组合物 | |
US20210030678A1 (en) | Cannabinoid and cbd liposome formulations and uses thereof | |
JP2005200339A (ja) | 抗菌剤 | |
US20040039050A1 (en) | Cryptotanshinone for preventing and alleviating alzheimer's disease | |
US3560612A (en) | Method of alleviating hypercitricemia | |
JP2022520665A (ja) | 液体プロポリス抽出物、その製剤およびその使用 | |
US10342802B2 (en) | Compositions comprising hydroxytyrosol and boswellic acid | |
US20220110946A1 (en) | Methods for administering compositions comprising hydroxytyrosol and boswellic acid | |
WO2022097764A1 (ko) | 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물 | |
JP2003026567A (ja) | 補酵素qを有効成分とする粘膜投与用組成物 | |
EP1212072B1 (de) | Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl | |
Siben et al. | Studying efficiency of the method of treating nematodoses in sheep | |
US3894153A (en) | Method of medical treatment of asthma | |
WO2019245177A1 (ko) | 무수황산나트륨, 황산칼륨, 무수황산마그네슘 및 시메티콘을 포함하는 장관하제 경구투여용 고형제제 조성물 | |
KR102058133B1 (ko) | 혼합제제 내 항생제 용해도를 향상시킬 수 있는 면역 증강용 조성물 및 이의 용도 | |
CN1224390C (zh) | 含吡咯并喹啉醌的治疗和预防脂肪肝的药物组合物 | |
EP0347927A2 (de) | Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on (Ebselen) zur Herstellung von Arzneimitteln zur Behandlung von Malaria | |
DE2422612C3 (de) | .Verwendung von 2,6-trans-Diphenylhexamethylcyclotetrasiloxan zur Herstellung eines oral oder intravenös verabreichbaren Arzneimittels zur Erhöhung des Dopamingehalts fan Gehirn von Tieren | |
US4443472A (en) | Method of treating mammals for effects of neuro- and cardiovascular toxins | |
CN116731218A (zh) | 一种菌菇多糖提取物及其制备方法和用途 | |
CA1221635A (fr) | Composition a activite pharmaceutique amelioree et utilisation de celle-ci pour des usages veterinaires | |
AU2021309398A1 (en) | A composition for treating helminth infestation in a non-human mammal | |
CN1555791A (zh) | 丹参酮ⅱa磺酸钠粉针注射剂及其制备方法 | |
JP2024021838A (ja) | フレイル予防剤、並びに、フレイル予防のための医薬品及び飲食品 | |
JPH1017484A (ja) | 真菌および白癬菌皮膚・粘膜感染症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081203 Termination date: 20210508 |